[uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management]

Bull Cancer. 2015 Sep;102(9):719-29. doi: 10.1016/j.bulcan.2015.05.003. Epub 2015 Jul 30.
[Article in French]
No abstract available

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / chemistry*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology
  • Chemotherapy, Adjuvant
  • Cost-Benefit Analysis
  • Disease-Free Survival
  • Female
  • Gene Expression Profiling / methods*
  • Humans
  • Neoplasm Metastasis
  • Neoplasm Proteins / analysis*
  • Plasminogen Activator Inhibitor 1 / analysis*
  • Predictive Value of Tests
  • Prognosis
  • Real-Time Polymerase Chain Reaction / methods*
  • Receptors, Urokinase Plasminogen Activator / analysis*
  • Receptors, Urokinase Plasminogen Activator / antagonists & inhibitors

Substances

  • Antineoplastic Agents
  • Neoplasm Proteins
  • Plasminogen Activator Inhibitor 1
  • Receptors, Urokinase Plasminogen Activator
  • SERPINE1 protein, human